Biocon has received regulatory approval for its drug Itolizumab to be used on coronavirus infected patients suffering from moderate to severe respiratory distress, the biopharmaceutical company said in a statement on Saturday. The drug, which is also used to cure the skin disease psoriasis, was cleared by the Drug Controller General of India (DCGI) for usage in the country.
"The randomised control trial indicated that all the patients treated with Itolizumab responded positively and recovered," said Kiran Mazumdar-Shaw, the firm's executive chairperson.
Read more...
Comments
Post a Comment